Brief Summary
This laboratory study is collecting and storing samples of tissue and blood from young patients with Hodgkin's lymphoma. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help the study of cancer in the future.
Brief Title
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma
Detailed Description
OBJECTIVES:
I. Establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid cell lines, host DNA, tumor and host RNA, serum, and plasma) and database linked to clinical features and outcomes from well-characterized cohorts of children and young adults with Hodgkin's lymphoma.
II. Provide specimens from diagnosis, early response evaluation, completion of chemotherapy and radiotherapy, long-term follow up, and relapse to study prognostic factors for early response, relapse, long-term outcomes, and identification of new biological targets for therapy.
OUTLINE: This is a multicenter study.
Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.
Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.
Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.
I. Establish a biologic specimen repository (of tumor tissue, tissue arrays, lymphoblastoid cell lines, host DNA, tumor and host RNA, serum, and plasma) and database linked to clinical features and outcomes from well-characterized cohorts of children and young adults with Hodgkin's lymphoma.
II. Provide specimens from diagnosis, early response evaluation, completion of chemotherapy and radiotherapy, long-term follow up, and relapse to study prognostic factors for early response, relapse, long-term outcomes, and identification of new biological targets for therapy.
OUTLINE: This is a multicenter study.
Patients enrolled on Hodgkin's lymphoma (HL) therapeutic clinical trials undergo collection of tumor tissue samples at baseline and at relapse or disease progression. Serum and anticoagulated peripheral blood samples are collected at baseline, at week 1, on day 1 of course 2, after completion of chemotherapy, after completion of radiotherapy, at 1 year after diagnosis, and at relapse or disease progression.
Patients with relapsed or progressive disease who plan to enroll on HL relapse/retrieval clinical trials undergo collection of tumor tissue, serum, and anticoagulated peripheral blood samples at relapse or disease progression.
Patients enrolled more than 1 year after completion of treatment undergo collection of tumor specimens, serum, and anticoagulated peripheral blood samples at time of clinical evaluation.
Completion Date
Completion Date Type
Actual
Conditions
Ann Arbor Stage I Childhood Hodgkin Lymphoma
Ann Arbor Stage II Childhood Hodgkin Lymphoma
Ann Arbor Stage III Childhood Hodgkin Lymphoma
Ann Arbor Stage IV Childhood Hodgkin Lymphoma
Refractory Childhood Hodgkin Lymphoma
Eligibility Criteria
Inclusion Criteria:
* Histologically confirmed Hodgkin's lymphoma (HL) meeting 1 of the following criteria:
* Newly diagnosed, untreated HL (for patients under 22 years of age)
* Past or present diagnosis of HL and past or present enrollment on a Children's Oncology Group (COG) or legacy HL clinical trial (for patients of any age)
* Histologically confirmed Hodgkin's lymphoma (HL) meeting 1 of the following criteria:
* Newly diagnosed, untreated HL (for patients under 22 years of age)
* Past or present diagnosis of HL and past or present enrollment on a Children's Oncology Group (COG) or legacy HL clinical trial (for patients of any age)
Inclusion Criteria
Inclusion Criteria:
* Histologically confirmed Hodgkin's lymphoma (HL) meeting 1 of the following criteria:
* Newly diagnosed, untreated HL (for patients under 22 years of age)
* Past or present diagnosis of HL and past or present enrollment on a Children's Oncology Group (COG) or legacy HL clinical trial (for patients of any age)
* Histologically confirmed Hodgkin's lymphoma (HL) meeting 1 of the following criteria:
* Newly diagnosed, untreated HL (for patients under 22 years of age)
* Past or present diagnosis of HL and past or present enrollment on a Children's Oncology Group (COG) or legacy HL clinical trial (for patients of any age)
Gender
All
Gender Based
false
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
NCT Id
NCT00900250
Org Class
Network
Org Full Name
Children's Oncology Group
Org Study Id
AHOD04B1
Overall Status
Completed
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
Hodgkin Disease (HD) Banking Study
Primary Outcomes
Outcome Measure
Biologic specimen repository and database
Outcome Time Frame
Baseline to up to 5 years
Secondary Ids
Secondary Id
NCI-2009-00378
Secondary Id
CDR0000495369
Secondary Id
COG-AHOD04B1
Secondary Id
AHOD04B1
Secondary Id
AHOD04B1
Secondary Id
U10CA180886
Secondary Id
U10CA098543
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Study Population
Patients newly diagnosed with HL or patients with HL enrolled (past or present) on COG or legacy HL clinical trials
Std Ages
Child
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
0
Investigators
Investigator Type
Principal Investigator
Investigator Name
Lisa Gennarini
Investigator Email
lfigueir@montefiore.org
Investigator Phone